Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ ALX4 Monoclonal Antibody (OTI1F2)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA526062
Description
ALX4 Monoclonal Antibody for Western Blot, IHC (P)
This gene encodes a paired-like homeodomain transcription factor expressed in the mesenchyme of developing bones, limbs, hair, teeth, and mammary tissue. Mutations in this gene cause parietal foramina 2 (PFM2); an autosomal dominant disease characterized by deficient ossification of the parietal bones. Mutations in this gene also cause a form of frontonasal dysplasia with alopecia and hypogonadism; suggesting a role for this gene in craniofacial development, mesenchymal-epithelial communication, and hair follicle development. Deletion of a segment of chromosome 11 containing this gene, del(11)(p11p12), causes Potocki-Shaffer syndrome (PSS); a syndrome characterized by craniofacial anomalies, mental retardation, multiple exostoses, and genital abnormalities in males. In mouse, this gene has been shown to use dual translation initiation sites located 16 codons apart.
Specifications
ALX4 | |
Monoclonal | |
1 mg/mL | |
PBS with 1% BSA, 50% glycerol and 0.02% sodium azide; pH 7.3 | |
Q9H161 | |
ALX4 | |
Full length human recombinant protein of ALX4 produced in HEK293T cell. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG1 |
Immunohistochemistry (Paraffin), Western Blot | |
OTI1F2 | |
Unconjugated | |
ALX4 | |
ALX homeobox 4; ALX4; ALX-4; aristaless 4; Aristaless-like 4; aristaless-like homeobox 4; CRS5; FND2; Homeobox protein aristaless-like 4; homeodomain transcription factor ALX4; KIAA1788; lst; Strong's luxoid | |
Mouse | |
Affinity Chromatography | |
RUO | |
60529 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction